Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Free Market Concept Not Applicable In Pharma Sector, Says India NPPA Chairman A.K. Banerjee: An Interview With PharmAsia News

This article was originally published in The Pink Sheet Daily

Executive Summary

Over half the population is uninsured, and unlike consumer durables where buying decisions depend on personal research and budget, in medicines their purchase decisions hinge on what is prescribed by doctors not by free choice, Banerjee argues.

You may also be interested in...



Indian Pricing Authority Intent On Recovering Funds From Drug Companies That Allegedly Overcharged Consumers

NEW DELHI - India's drug price regulator, the National Pharmaceutical Pricing Authority, which monitors and fixes drug prices and their availability in India, has accelerated its efforts to recover $411 million that drug manufacturers have allegedly overcharged consumers for controlled drugs in the last 12 years

India’s Insulin Market Set For Sparks As Two Large Players Challenge The Dominance Of Sanofi-Aventis’ Lantus

MUMBAI - For nearly a decade, the world's fourth-largest drug maker, Sanofi-Aventis, has had a free play in India in marketing its world-famous insulin brand Lantus, the only long-acting basal insulin, widely prescribed for its ability to slowly release insulin into the body. Now that could change as two large Indian players, Wockhardt and Biocon, are looking at chipping away some of this lucrative and growing market through their own brand launches

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel